Mark Talamonti to Cisplatin
This is a "connection" page, showing publications Mark Talamonti has written about Cisplatin.
Connection Strength
0.048
-
Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292). Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e607-13.
Score: 0.021
-
Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010 Jun 01; 101(7):587-92.
Score: 0.020
-
Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study. Int J Radiat Oncol Biol Phys. 1996 Jul 01; 35(4):745-9.
Score: 0.007